Fig. 2From: Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitusa LDL-C levels of patients without and with T2D 2. b Number and percentage of achievement of treatment targets according to diabetes status. Data are median (interquartile range). *Indicates statistical significance when compared to baseline LDL-C levels (for all groups investigated)Back to article page